$16.65
▼ -1.4% Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?
Viatris' China Policy Concerns Overstated, UBS Says
Overview
52-week range
$9.43
$18
81% of range
Avg surprise (last 3)
+8.7%
Avg reaction (last 2)
+7.4%
100% positive
Latest IV / EM
21%
EM ±3.3% · $17 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.10 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $0.59 | $0.52 | +13.5% | +18.0% | +9.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.11 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $0.62 | $0.56 | +10.7% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $0.50 | $0.49 | +2.0% | — | +5.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.08 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.27 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.09 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.27 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.22 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.19 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.76B | $3.52B | — | $3.76B | $3.58B | $3.25B | — | $3.75B |
| Cost of revenue | $2.30B | $2.36B | — | $2.39B | $2.25B | $2.09B | — | $2.29B |
| Gross profit | $1.46B | $1.16B | — | $1.37B | $1.33B | $1.16B | — | $1.46B |
| Operating income | $6M | $-80M | — | $179M | $233M | $-2.88B | — | $226M |
| Net income | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.10 | $0.15 | — | $-0.11 | — | $-2.55 | — | $0.08 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $886M | $1.80B | $1.32B | $975M | $566M | $755M | $735M | $1.88B |
| Inventory | $3.93B | $3.93B | $4.00B | $4.11B | $4.26B | $4.10B | $3.85B | $4.08B |
| Total current assets | $10.06B | $10.92B | $9.79B | $9.95B | $9.77B | $9.62B | $9.52B | $11.31B |
| Total assets | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | $38.47B | $41.50B | $44.75B |
| Long-term debt | $11.61B | $12.41B | $12.48B | $12.49B | $12.79B | $14.18B | $14.04B | $14.30B |
| Total liabilities | $20.78B | $22.18B | $22.48B | $22.70B | $22.84B | $22.82B | $22.87B | $24.96B |
| Total equity | $14.26B | $14.66B | $14.71B | $15.22B | $15.57B | $15.65B | — | $19.79B |